North America Chlorpheniramine Maleate Market Report and Forecast 2024-2032

North America Chlorpheniramine Maleate Market Outlook

The global chlorpheniramine maleate market size was valued at USD 514.9 million in 2023, with North America holding a significant market share. The market is driven by the rising prevalence of allergic conditions. It is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to attain USD 848.1 million by 2032.

Key Takeaways

• In the United States, allergic rhinitis affects 20-30% of adults and around 40% of children. This rising prevalence of allergic conditions is expected to directly impact the market demand.

• The launch of innovative medicines, with chlorpheniramine maleate as an essential ingredient, is likely to augment the North America chlorpheniramine maleate market share . In September 2023, Genexa introduced the Kids’ Daytime + Nighttime Cough Relief Value Pack with the nighttime product containing 2 mg of chlorpheniramine maleate.

• Robust research efforts are anticipated to lead to a broader range of chlorpheniramine maleate-based medications entering the market. In September 2023, Dr. Ferrer Biopharma revealed the potential of Intranasal Chlorpheniramine Maleate (iCPM) in reducing post-COVID symptoms by 90%, in comparison to a placebo.

North America Chlorpheniramine Maleate Market Analysis

Chlorpheniramine maleate is an antihistamine that is commonly used to relieve symptoms such as watery eyes, runny nose, common cold, and rash from allergies, among others. It works by blocking a chemical released during an allergic reaction called histamine. Heightened patient awareness regarding allergy management, increased access to medications, and rising disposable incomes are some of the factors that are contributing to the North America chlorpheniramine maleate market growth.

The market is also driven by the rising prevalence of various allergic conditions such as seasonal allergies and allergic rhinitis in North America. Population studies reveal that allergic rhinitis is highly prevalent in the United States, with the condition affecting 20-30% of adults and around 40% of children. Moreover, allergic rhinitis treatment takes a significant portion of healthcare costs. Thus, the increasing cases of such allergic conditions are expected to impact the market demand for chlorpheniramine maleate in the coming years.

The North America chlorpheniramine maleate market demand is experiencing a surge, owing to the advancement of drug formulations that supports the development of highly effective chlorpheniramine maleate products with reduced side effects. In September 2023, Genexa, a clean medicine company based in the United States, introduced new clean over the counter (OTC) medicines for kids, which included Kids’ Daytime + Nighttime Cough Relief Value Pack. The nighttime product in the value pack contains 15 mg of dextromethorphan HBr and 2 mg of chlorpheniramine maleate. The oral product does not contain any artificial fillers compared to the competitors’ products and is effective for cough management and relieves sneezing and runny nose. The launch of such innovative medicines, having chlorpheniramine maleate as an essential ingredient, is likely to augment the market value in the forecast period.

One of the major North America chlorpheniramine maleate market trends is the increased investment in research and development of chlorpheniramine maleate-based products by the key market players. In September 2023, Dr. Ferrer Biopharma, a leading pharmaceutical company in Florida, revealed the potential of Intranasal Chlorpheniramine Maleate (iCPM) in treating post-COVID-19 long-term symptoms. The findings from two randomized controlled trials (ACCROS I and ACCROS III) were presented at the European Respiratory Society (ERS) Congress 2023. It demonstrated intranasal chlorpheniramine's ability to reduce post-COVID symptoms by 90% compared to placebo. Such intensive research efforts are anticipated to lead to a broader range of chlorpheniramine maleate-based medications entering the market, thereby boosting market growth.

North America Chlorpheniramine Maleate Market Segmentation

The report offers a detailed analysis of the market based on the following segments:
 

North America Chlorpheniramine Maleate Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Pfizer Inc.

• Johnson & Johnson

• Sanofi

• Zydus Lifesciences Limited

• GlaxoSmithKline Plc

• Capellon Pharmaceuticals

• Merck & Co., Inc.

• Alkem Laboratories Ltd.

• Viatris Inc.

• Bayer AG

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report